|
[1]
|
Charlson, F.J., Ferrari, A.J., Santomauro, D.F., Diminic, S., Stockings, E., Scott, J.G., et al. (2018) Global Epidemiology and Burden of Schizophrenia: Findings from the Global Burden of Disease Study 2016. Schizophrenia Bulletin, 44, 1195-1203. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Jaaskelainen, E., Juola, P., Hirvonen, N., McGrath, J.J., Saha, S., Isohanni, M., et al. (2012) A Systematic Review and Meta-Analysis of Recovery in Schizophrenia. Schizophrenia Bulletin, 39, 1296-1306. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Shi, C., Wu, F. and Xu, J. (2012) Incorporation of Β-Sitosterol into Mitochondrial Membrane Enhances Mitochondrial Function by Promoting Inner Mitochondrial Membrane Fluidity. Journal of Bioenergetics and Biomembranes, 45, 301-305. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Shi, C., Luo, X., Wang, J. and Long, D. (2015) Incorporation of Β-Sitosterol into the Membrane Prevents Tumor Necrosis Factor-α-Induced Nuclear Factor-κB Activation and Gonadotropin-Releasing Hormone Decline. Steroids, 96, 1-6. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
鲍姝畅, 李松哲, 蔡凌云, 等. 常春藤皂苷元及其衍生物的药理作用及分子机制研究进展[J]. 中国医药, 2024, 19(7): 1083-1086.
|
|
[6]
|
Park, S.J., Kim, D.H., Jung, J.M., Kim, J.M., Cai, M., Liu, X., et al. (2012) The Ameliorating Effects of Stigmasterol on Scopolamine-Induced Memory Impairments in Mice. European Journal of Pharmacology, 676, 64-70. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Funk, A.J., McCullumsmith, R.E., Haroutunian, V. and Meador-Woodruff, J.H. (2011) Abnormal Activity of the MAPK-and Camp-Associated Signaling Pathways in Frontal Cortical Areas in Postmortem Brain in Schizophrenia. Neuropsychopharmacology, 37, 896-905. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Jeffries, M.A., Urbanek, K., Torres, L., Wendell, S.G., Rubio, M.E. and Fyffe-Maricich, S.L. (2016) ERK1/2 Activation in Preexisting Oligodendrocytes of Adult Mice Drives New Myelin Synthesis and Enhanced CNS Function. Journal of Neuroscience, 36, 9186-9200. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Tidyman, W.E. and Rauen, K.A. (2009) The Rasopathies: Developmental Syndromes of Ras/MAPK Pathway Dysregulation. Current Opinion in Genetics & Development, 19, 230-236. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Craddock, R.M., Lockstone, H.E., Rider, D.A., Wayland, M.T., Harris, L.J.W., McKenna, P.J., et al. (2007) Altered T-Cell Function in Schizophrenia: A Cellular Model to Investigate Molecular Disease Mechanisms. PLOS ONE, 2, e692. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Upthegrove, R. and Barnes, N.M. (2014) The Immune System and Schizophrenia: An Update for Clinicians. Advances in Psychiatric Treatment, 20, 83-91. [Google Scholar] [CrossRef]
|
|
[12]
|
Chenniappan, R., Nandeesha, H., Kattimani, S. and Nanjaiah, N.D. (2020) Interleukin-17 and Interleukin-10 Association with Disease Progression in Schizophrenia. Annals of Neurosciences, 27, 24-28. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Gonzalez-Liencres, C., Tas, C., Brown, E.C., Erdin, S., Onur, E., Cubukcoglu, Z., et al. (2014) Oxidative Stress in Schizophrenia: A Case-Control Study on the Effects on Social Cognition and Neurocognition. BMC Psychiatry, 14, Article No. 268. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Kabbani, N., P. Woll, M., C. Nordman, J. and Levenson, R. (2012) Dopamine Receptor Interacting Proteins: Targeting Neuronal Calcium Sensor-1/D2 Dopamine Receptor Interaction for Antipsychotic Drug Development. Current Drug Targets, 13, 72-79. [Google Scholar] [CrossRef] [PubMed]
|